The Push for Generics Challenges Manufacturers

Biotech firms face new issues as FDA weighs policies to streamline generic-drug approvals and reduce patent disputes.

Related Content:

Quality SystemsRegulatory WatchGeneric DrugsDosage FormsPharmaceutical Technology-07-02-2003

Congress Slated to Reauthorize User Fees without FDA “Improvements”

The Manufacturing Edge on Path to Market

FDA Approves Bluebird Bio’s $3 Million CALD Treatment